Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2025 Financial Results
Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has reported its fiscal Q1 2025 financial results. The company's revenue increased to $7.97 million from $7.85 million in Q1 2024, primarily consisting of $7.87 million in processing and storage fees.
Net income decreased to $283,000 ($0.03 per share) compared to $556,000 ($0.07 per share) in the same period last year. The company serves over 500,000 parents from 87 countries and operates a public banking program with Duke University that has provided cord blood for more than 600 transplantations.
Cryo-Cell International (NYSE: CCEL), la prima banca privata al mondo di sangue cordonale, ha comunicato i risultati finanziari del primo trimestre fiscale 2025. I ricavi dell'azienda sono aumentati a 7,97 milioni di dollari rispetto ai 7,85 milioni di dollari del primo trimestre 2024, principalmente derivanti da 7,87 milioni di dollari in commissioni di lavorazione e conservazione.
L'utile netto è diminuito a 283.000 dollari (0,03 dollari per azione) rispetto a 556.000 dollari (0,07 dollari per azione) nello stesso periodo dell'anno precedente. L'azienda serve oltre 500.000 genitori in 87 paesi e gestisce un programma di banca pubblica con la Duke University che ha fornito sangue cordonale per più di 600 trapianti.
Cryo-Cell International (NYSE: CCEL), el primer banco privado de sangre de cordón umbilical del mundo, ha informado sus resultados financieros del primer trimestre fiscal de 2025. Los ingresos de la compañía aumentaron a 7,97 millones de dólares desde 7,85 millones en el primer trimestre de 2024, principalmente por 7,87 millones en tarifas de procesamiento y almacenamiento.
La utilidad neta disminuyó a 283,000 dólares (0,03 dólares por acción) en comparación con 556,000 dólares (0,07 dólares por acción) en el mismo período del año anterior. La empresa atiende a más de 500,000 padres de 87 países y opera un programa de banco público con la Universidad de Duke que ha proporcionado sangre de cordón para más de 600 trasplantes.
Cryo-Cell International (NYSE: CCEL)는 세계 최초의 민간 제대혈 은행으로, 2025 회계연도 1분기 재무 실적을 발표했습니다. 회사의 매출은 2024년 1분기 785만 달러에서 797만 달러로 증가했으며, 주로 787만 달러의 처리 및 보관 수수료로 구성되어 있습니다.
순이익은 28만 3천 달러(주당 0.03달러)로, 전년 동기 55만 6천 달러(주당 0.07달러) 대비 감소했습니다. 회사는 87개국의 50만 명 이상의 부모를 지원하며, 듀크 대학교와 함께 600건 이상의 이식에 사용된 제대혈을 제공하는 공공 은행 프로그램을 운영하고 있습니다.
Cryo-Cell International (NYSE : CCEL), la première banque privée mondiale de sang de cordon, a publié ses résultats financiers du premier trimestre fiscal 2025. Le chiffre d'affaires de la société a augmenté pour atteindre 7,97 millions de dollars contre 7,85 millions au premier trimestre 2024, principalement constitué de 7,87 millions de dollars de frais de traitement et de stockage.
Le bénéfice net a diminué à 283 000 dollars (0,03 dollar par action) contre 556 000 dollars (0,07 dollar par action) sur la même période l'an dernier. L'entreprise dessert plus de 500 000 parents dans 87 pays et gère un programme de banque publique avec l'Université Duke qui a fourni du sang de cordon pour plus de 600 transplantations.
Cryo-Cell International (NYSE: CCEL), die weltweit erste private Nabelschnurblutbank, hat ihre Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 veröffentlicht. Der Umsatz des Unternehmens stieg auf 7,97 Millionen US-Dollar gegenüber 7,85 Millionen US-Dollar im ersten Quartal 2024, hauptsächlich bestehend aus 7,87 Millionen US-Dollar an Verarbeitungs- und Lagergebühren.
Der Nettogewinn sank auf 283.000 US-Dollar (0,03 US-Dollar pro Aktie) im Vergleich zu 556.000 US-Dollar (0,07 US-Dollar pro Aktie) im gleichen Zeitraum des Vorjahres. Das Unternehmen betreut über 500.000 Eltern aus 87 Ländern und betreibt ein öffentliches Bankprogramm mit der Duke University, das Nabelschnurblut für mehr als 600 Transplantationen bereitgestellt hat.
- Revenue increased 1.5% YoY to $7.97 million
- Processing and storage fee revenue grew to $7.87 million
- Public banking revenue nearly doubled to $82,000 from $44,000
- Product revenue increased to $21,000 from $3,000
- Net income declined 49% YoY to $283,000
- Earnings per share decreased from $0.07 to $0.03
Insights
Cryo-Cell's Q1 2025 results present a concerning financial picture despite modest top-line growth. While revenue increased by
Breaking down the revenue components:
- Processing and storage fees:
$7.87 million (vs.$7.81 million in Q1 2024) - Product revenue:
$21,000 (vs.$3,000 in Q1 2024) - Public banking revenue:
$82,000 (vs.$44,000 in Q1 2024)
The stark contrast between revenue growth and profit performance indicates significant margin compression. While the company continues its strategic initiatives - including the Duke University partnership and ExtraVault expansion into biopharmaceutical services - the financial results suggest challenges in maintaining profitability during this transition period.
For a small-cap company with a market capitalization of approximately
Without management commentary addressing the specific factors behind the profit decline, investors lack visibility into whether this represents temporary growth-related investments or more structural issues with the business model or cost structure.
Financial Results
Revenue
The revenues for the first quarter of fiscal 2025 were
Net Income
The Company reported net income of approximately
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the
Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. In February 2021, Cryo-Cell entered into a license agreement with Duke University that the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, vertically integrated cellular therapy company. In March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. For more information, please visit (www.extravault.com).
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-Q filed on April 14, 2025.
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415154546/en/
Irene Smith
813-749-2102
Ismith@cryo-cell.com
Source: Cryo-Cell International, Inc.
FAQ
What was Cryo-Cell's (CCEL) revenue in Q1 2025?
How much did CCEL's net income decrease in Q1 2025?
What are the main revenue sources for Cryo-Cell (CCEL) in Q1 2025?
How many transplantations has CCEL's public banking program supported?
What was CCEL's earnings per share (EPS) in Q1 2025?
